Journal ArticleDOI
Management of gastric cancer in Asia: resource-stratified guidelines
Lin Shen,Yan Shen Shan,Huang Ming Hu,Timothy J. Price,Bhawna Sirohi,Kun-Huei Yeh,Yi-Hsin Yang,Takeshi Sano,Han-Kwang Yang,Xiaotian Zhang,Sook Ryun Park,Masashi Fujii,Yoon-Koo Kang,Li-Tzong Chen,Li-Tzong Chen +14 more
TLDR
This work aims to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries, using the categories of basic, limited, enhanced, and maximum level.Abstract:
Summary Gastric cancer is the fourth most common cancer globally, and is the second most common cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in 2008 were from Asian countries. With a high mortality-to-incidence ratio, management of gastric cancer is challenging. We discuss evidence for optimum management of gastric cancer in aspects of screening and early detection, diagnosis, and staging; endoscopic and surgical intervention; and the concepts of perioperative, postoperative, and palliative chemotherapy and use of molecularly targeted therapy. Recommendations are formulated on the basis of the framework provided by the Breast Health Global Initiative, using the categories of basic, limited, enhanced, and maximum level. We aim to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries.read more
Citations
More filters
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013.
Maigeng Zhou,Haidong Wang,Jun Zhu,Wanqing Chen,Linhong Wang,Shiwei Liu,Yichong Li,Lijun Wang,Yunning Liu,Peng Yin,Jiangmei Liu,Shicheng Yu,Feng Tan,Ryan M Barber,Matthew M Coates,Daniel Dicker,Maya S Fraser,Diego Gonzalez-Medina,Hannah Hamavid,Yuantao Hao,Guoqing Hu,Guohong Jiang,Haidong Kan,Alan D. Lopez,Michael R. Phillips,Michael R. Phillips,Jun She,Theo Vos,Xia Wan,Gelin Xu,Lijing L. Yan,Chuanhua Yu,Yong Zhao,Yingfeng Zheng,Xiaonong Zou,Mohsen Naghavi,Yu Wang,Christopher J L Murray,Gonghuan Yang,Xiaofeng Liang +39 more
TL;DR: The most common non-communicable diseases, including ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and cancers (liver, stomach, and lung), contributed much more to YLLs in 2013 compared with 1990, and road injuries have become a top ten cause of death in all provinces in mainland China.
Journal ArticleDOI
Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype
Ana Ferro,Bárbara Peleteiro,Matteo Malvezzi,Cristina Bosetti,Paola Bertuccio,Fabio Levi,Eva Negri,Carlo La Vecchia,Carlo La Vecchia,Nuno Lunet +9 more
TL;DR: Despite the favourable mortality trends worldwide, in some countries the declines are becoming less marked, and the predictions for 2015 show that a levelling off of rates is expected in the USA and a few other countries.
Journal ArticleDOI
Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality
Jae Kwan Jun,Kui Son Choi,Hoo Yeon Lee,Mina Suh,Boyoung Park,Seung Hoon Song,Kyu-Won Jung,Chan Wha Lee,Il Ju Choi,Eun Cheol Park,Dukhyoung Lee +10 more
TL;DR: Within the Korean National Cancer Screening Program, patients who received an upper endoscopy were less likely to die from gastric cancer; no associations were found for UGI series.
Journal ArticleDOI
Genetics of gastric cancer.
Mairi H. McLean,Emad M. El-Omar +1 more
TL;DR: The genetic basis of gastric cancer will offer insights into its pathogenesis, help identify new biomarkers and novel treatment targets, aid prognostication and could be central to developing individualized treatment strategies in the future.
References
More filters
Journal ArticleDOI
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
Kensei Yamaguchi,Akira Sawaki,Toshihiko Doi,Taroh Satoh,Yasuhide Yamada,Yasushi Omuro,Tomohiro Nishina,Narikazu Boku,Keisho Chin,Yasuo Hamamoto,Hiroya Takiuchi,Yoshito Komatsu,Shigehira Saji,Wasaburo Koizumi,Yoshinori Miyata,Atsushi Sato,Eishi Baba,Takao Tamura,Takashi Abe,Atsushi Ohtsu +19 more
TL;DR: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.
A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer.
TL;DR: The model suggests that the ICER of adjuvant chemoradiotherapy for resected gastric cancer compares favorably to other widely used cancer treatments.
Journal ArticleDOI
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.
Emilio Bajetta,Irene Floriani,Maria Di Bartolomeo,Roberto Labianca,Lorenza Landi,Armando Santoro,Rossanna Casaretti,Enzo Pasquini,Francesca Di Fabio,Ermanno Rondini,Graziella Pinotti,Paolo Bidoli,Gerado Rosati,Andrea Mambrini,A. Ciarlo,Stefano Cordio,Sergio Ricci,L. Frassineti,Francesco Di Costanzo,Anna Maria Bochicchio +19 more
TL;DR: Adjuvant chemotherapy in gastric cancer with more intensive regimen did not result in a significant prolongation of DFS and OS when compared to bolus/infusion FU/LV regimen.
Journal ArticleDOI
A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Rui-Hua Xu,Guo-ping Sun,Hui-shan Lu,Liu Yun Peng,Jianming Xu,Meizuo Zhong,Helong Zhang,Shiying Yu,Wei Li,Xiao-hua Hu,Jie Jun Wang,Ying Cheng,Jun-tian Zhou,Zengqing Guo,Zhongzhen Guan +14 more
TL;DR: A combination of S-1 and cisplatin has been shown to be effective and safe for the first-line treatment of advanced gastric cancer in Japan and this is the first randomized trial of this combination.
Journal ArticleDOI
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.
Min-Hee Ryu,Eishi Baba,Kyung Hee Lee,Narikazu Boku,Young Iee Park,Ichinosuke Hyodo,Byung-Ho Nam,Taito Esaki,Baek-Yeol Ryoo,Eun-Kee Song,Sang-Hee Cho,Sung Sook Lee,Won Ki Kang,Sung Hyun Yang,Dae Young Zang,Dong Bok Shin,Sook Ryun Park,K. Shinozaki,Toshimi Takano,Yoon-Koo Kang +19 more
TL;DR: This SOS study was a multicenter, randomized, open-label, phase III study to evaluate whether SP3 was non-inferior/superior to SP5 in terms of progression-free survival (PFS) determined by a blinded central radiology review according to RECIST v1.1.